ClinicalTrials.gg
CompletedNCT07127770Updated Dec 19, 2025

A Study to Understand How the Body Processes [14C]PF-07104091 in Healthy Participants

A Phase 1 interventional study of PF-07104091 in Healthy Adults, sponsored by Pfizer. Completed at 1 site in Netherlands. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-19.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Oct 2025, 1 year 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
Male
01

Study summary

The purpose of this study is to learn how the body processes the study medicine PF-07104091.

The study is seeking participants who are:

- Healthy male aged 18 to 65 years of age

Participants in the study will receive 14C-labeled PF-07104091 by mouth after a meal. After 14 days, the participants will receive PF-07104091 by mouth (after a meal) followed by IV fusion (given directly into a vein) of microdose [14C]PF-07104091.

The study will help understand how the body processes study medicine PF-07104091 and how the medicine is changed and removed from the body after you take it. This study will also help to understand how much PF-07104901 is taken up into the blood.

Participants will remain in the study clinic for a maximum of 23 days and will have one follow-up contact.

02

Conditions studied

  • Healthy Adults

Keywords

  • Pharmacokinetics
  • Healthy Volunteers
  • Biological Availability
  • Absorption
  • Elimination
  • Distribution
  • ADME
  • Bioavailability
  • Radiolabeled
  • Metabolic Profile
  • Renal Elimination
  • Mass Balance
  • Small molecule
  • Absolute Bioavailability
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and standard 12-lead ECGs.
  • (BMI) of 17.5-32.0 kg/m2 inclusive and a total body weight >50 kg (110 lb)
  • Evidence of a personally signed and dated Document (ICD) indicating that the participant has been informed of all pertinent aspects of the study.
  • Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Regimen A; Period 1

    Single oral dose of 14C-labeled PF-07104091 administered under fed conditions.

    Drug: PF-07104091

  • Experimental
    Regimen B; Period 2

    Single oral dose of unlabeled PF-07104091 administered under fed conditions followed by an intravenous (IV) infusion of PF-07104091 containing a microdose of 14C-labeled PF-07104091.

    Drug: PF-07104091

Interventions

  • DrugPF-07104091

    Cyclin-dependent kinase-2 inhibitor

06

What researchers measure

Primary outcomes

  1. Percentage of Total Radiocarbon (14c) excreted in urine

    Percentage of 14C excreted in urine following 14C PF-07104091 single dose administration will be determined as: (Total 14C urine/ 14C dose administered) \*100 where, 14C dose was administered dose of 14C PF-07104091.

    Time frame: From Predose up to 14 days post dose of period 1 and 2

  2. Percentage of Total Radiocarbon (14c) excreted in feces

    Percentage of 14C excreted in feces following 14C PF-07104091 single dose administration will be determined as: (Total 14C feces/ 14C dose administered) \*100 where, 14C dose was administered dose of 14C PF-07104091.

    Time frame: From Predose up to 14 days post dose of period 1 (and if applicable for Period 2)

  3. Percentage of Total Radiocarbon (14c) excreted in vomitus (if applicable)

    Percentage of 14C excreted in vomitus (if applicable) following 14C PF-07104091 single dose administration will be determined as: (Total 14C vomitus/ 14C dose administered) \*100 where, 14C dose was administered dose of 14C PF-07104091.

    Time frame: From Predose up to 14 days post dose of period 1 only

  4. Cumulative Percent Recovery of Total Radiocarbon (14C)

    Percentage recovery of total radioactivity (14C) in urine, feces, and vomitus (If applicable) was determined based on total administered dose.

    Time frame: From Predose up to 14 days post dose of period 1 only

  5. Percentage of Metabolite Detected in Plasma After Oral Administration of PF-07104091

    The percentage of major metabolites detected in plasma after oral administration of PF-07104091

    Time frame: From Predose to 14 days post dose of period 1

  6. Percentage of Metabolite Detected in Urine After Oral Administration of PF-07104091

    The percentage of major metabolites detected in urine after oral administration of PF-07104091

    Time frame: From Predose to 14 days post dose of period 1

  7. Percentage of Metabolite Detected in Feces After Oral Administration of PF-07104091

    The percentage of major metabolites detected in feces after oral administration of PF-07104091

    Time frame: From Predose to 14 days post dose of period 1

Secondary outcomes

  1. Oral Absolute Bioavailability

    Dose normalized AUCinf (AUCinf\[dn\]) will be calculated as AUCinf/Dose, where AUCinf is the area under the plasma concentration-time profile from time 0 extrapolated to infinite time. Absolute oral bioavailability is defined as the ratio of geometric mean of AUCinf(dn) following orally administered PF-07104091 (i.e., unlabeled PF-07104091) to AUCinf(dn) following intravenously administered \[14C\]PF-07104091 in period 2.

    Time frame: From Predose up to 14 days post dose, period 2 only.

  2. Fraction of PF-07104091 Dose Absorbed (Fa)

    Fraction of dose absorbed (Fa) will be estimated as the ratio of total or partial radioactivity (dose normalized) excreted into the urine (from time 0 to the time of last measurable concentration) following oral and IV administration of \[14C\]PF-07104091 microtracer dose in Period 1 and 2, respectively.

    Time frame: From Predose up to 14 days post dose

  3. Number of Participants with Clinically Significant Abnormalities in Laboratory Parameters

    Time frame: From baseline up to 35 days after the last dose of study intervention (up to Day 36)

  4. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    Time frame: From baseline up to 35 days after the last dose of study intervention (up to Day 36)

  5. Number of Participants With Clinically Significant Abnormalities in Vital Signs

    Time frame: From baseline up to 35 days after the last dose of study intervention (up to Day 36)

  6. Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities

    Time frame: From baseline up to 35 days after the last dose of study intervention (up to Day 36)

07

Study locations

1 site
  • ICON
    Groningen, 9728 NZ, Netherlands
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2025 to primary completion in Oct 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2025
First posted
Aug 17, 2025
StartActual
Aug 28, 2025
Primary completionActual
Oct 8, 2025
CompletionActual
Nov 7, 2025
Last update
Dec 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07127770
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 17, 2025
Start date
Aug 28, 2025
Primary completion
Oct 8, 2025
Completion
Nov 7, 2025
Last update
Dec 19, 2025

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion